1. |
GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 2017, 390(10100): 1260-1344.
|
2. |
Mohan KM, Wolfe CD, Rudd AG, et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke, 2011, 42(5): 1489-1494.
|
3. |
Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis after emergency department diagnosis of TIA. JAMA, 2000, 284(22): 2901-2906.
|
4. |
杨卉, 王赤波, 梁辉. 肾素-血管紧张素系统与卒中. 国外医学 (脑血管疾病分册), 2001, 9(4): 227-229.
|
5. |
梁辉, 范金英, 周盛年. 肾素-血管紧张素系统与缺血性脑血管病. 中华神经医学杂志, 2003, (4): 312-314.
|
6. |
Saavedra JM, Benicky J, Zhou J. Mechanisms of the anti-ischemic effect of angiotensin Ⅱ at (1) receptor antagonists in the Brain. Cell Mol Neurobiol, 2006, 26(7-8): 1099-1111.
|
7. |
Wang WT, You LK, Chiang CE, et al. Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: traditional and bayesian network meta-analysis of randomized trials. Medicine, 2016, 95(15): e3302.
|
8. |
Lee M, Saver JL, Hong KS, et al. Renin-angiotensin system modulators modestly reduce vascular risk in persons with prior stroke. Stroke, 2012, 43(1): 113-119.
|
9. |
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation, 2018, 138(17): e426-e483.
|
10. |
李伦, 田金徽, 姚亮, 等. 网状 Meta 分析的统计学基础、假设和证据质量评估. 循证医学, 2015, 15(3): 180-183.
|
11. |
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med, 2015, 162(11): 777-784.
|
12. |
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ, 2003, 327(7414): 557-560.
|
13. |
Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med, 2001, 20(4): 641-654.
|
14. |
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997, 315(7109): 629-634.
|
15. |
Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol, 2011, 64(2): 163-171.
|
16. |
Ogihara T, Nakao K, Fukui T, et al. The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res, 2008, 31(8): 1595-1601.
|
17. |
Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med, 2000, 342(3): 145-153.
|
18. |
Sleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet, 2001, 358(9299): 2130-2131.
|
19. |
Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke, 2003, 34(11): 2741-2748.
|
20. |
Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ, 2002, 324(7339): 699-702.
|
21. |
Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med, 2008, 359(12): 1225-1237.
|
22. |
Weinberger J. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Curr Cardiol Rep, 2003, 5(2): 140.
|
23. |
Trenkwalder P, Elmfeldt D, Hofman A, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE)-major CV events and stroke in subgroups of patients. Blood Press, 2005, 14(1): 31-37.
|
24. |
Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens, 2006, 24(11): 2163-2168.
|
25. |
中国脑卒中防治血压管理指导规范. 中国脑卒中防治血压管理指导规范. 实用心脑肺血管病杂志, 2017, 25(10): 87.
|
26. |
Savaskan E. The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr Alzheimer Res, 2005, 2(1): 29-35.
|
27. |
王拥军. 血管紧张素受体拮抗剂在改善脑卒中患者预后中的作用. 中华高血压杂志, 2012, 20(5): 411-413.
|
28. |
姜馨, 吕卓人. 血管紧张素Ⅱ受体拮抗剂和血管紧张素转换酶抑制剂的脑保护作用之差异. 中华心血管病杂志, 2006, 34(12): 1143-1145.
|
29. |
Vidt DG. Telmisartan, ramipril, or both in patients at high risk for vascular events. Curr Hypertens Rep, 2008, 10(5): 343-344.
|
30. |
Diener HC. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs. J Hypertens Suppl, 2009, 27(5): S31-S36.
|
31. |
曾宪涛, 沈可, 罗杰. Meta 分析系列之十二: 分配隐藏的评价. 中国循证心血管医学杂志, 2013, 5(3): 219-221.
|
32. |
曾宪涛, 熊期, 沈可. Meta 分析系列之十三: 盲法的评价. 中国循证心血管医学杂志, 2013, 5(4): 331-333.
|
33. |
Schrader J, Lüders S, Kulschewski A, et al. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke, 2003, 34(7): 1699-1703.
|
34. |
Jusufovic M, Sandset EC, Bath PM, et al. Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis. Int J Stroke, 2015, 10(3): 354-359.
|
35. |
中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南 2018. 中华神经科杂志, 2018, 51(9): 666-682.
|
36. |
国家卫生健康委员会急诊医学质控中心, 中国医师协会急诊医师分会, 世界中医药学会联合会急症专业委员会. 中国急性缺血性脑卒中急诊诊治专家共识. 中国急救医学, 2018, 38(4): 281-287.
|